JP2010507096A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010507096A5 JP2010507096A5 JP2009533355A JP2009533355A JP2010507096A5 JP 2010507096 A5 JP2010507096 A5 JP 2010507096A5 JP 2009533355 A JP2009533355 A JP 2009533355A JP 2009533355 A JP2009533355 A JP 2009533355A JP 2010507096 A5 JP2010507096 A5 JP 2010507096A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- iap
- methylamino
- cyclohexyl
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- -1 1-cyclohexyl-2- {2- [5- (4-fluoro-phenoxy) -pyridin-3-yl] -pyrrolidin-1-yl} -2-oxo-ethyl Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- QKNFFJHHPCWXTH-UHFFFAOYSA-N 2-(methylamino)propanamide Chemical compound CNC(C)C(N)=O QKNFFJHHPCWXTH-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 208000016361 genetic disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- IWKCMACULCSOIW-UHFFFAOYSA-N n-[1-cyclohexyl-2-[ethyl-[1-[5-(4-fluorobenzoyl)pyridin-3-yl]propyl]amino]-2-oxoethyl]-2-(methylamino)propanamide Chemical compound C=1N=CC(C(=O)C=2C=CC(F)=CC=2)=CC=1C(CC)N(CC)C(=O)C(NC(=O)C(C)NC)C1CCCCC1 IWKCMACULCSOIW-UHFFFAOYSA-N 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 229940080818 propionamide Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86216106P | 2006-10-19 | 2006-10-19 | |
| US86215506P | 2006-10-19 | 2006-10-19 | |
| PCT/US2007/022125 WO2008057172A2 (en) | 2006-10-19 | 2007-10-17 | Organic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010507096A JP2010507096A (ja) | 2010-03-04 |
| JP2010507096A5 true JP2010507096A5 (enExample) | 2010-11-25 |
Family
ID=39364966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009533355A Pending JP2010507096A (ja) | 2006-10-19 | 2007-10-17 | 有機化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20100316573A1 (enExample) |
| EP (1) | EP2076778A2 (enExample) |
| JP (1) | JP2010507096A (enExample) |
| KR (1) | KR20090082221A (enExample) |
| AU (1) | AU2007318220A1 (enExample) |
| BR (1) | BRPI0717411A2 (enExample) |
| CA (1) | CA2665838A1 (enExample) |
| MX (1) | MX2009004061A (enExample) |
| RU (1) | RU2009118487A (enExample) |
| WO (1) | WO2008057172A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5230865B2 (ja) | 2004-07-15 | 2013-07-10 | テトラロジック ファーマシューティカルズ コーポレーション | Ｉａｐ結合性化合物 |
| DK1851200T3 (da) | 2005-02-25 | 2014-04-14 | Tetralogic Pharm Corp | Dimere iap-inhibitorer |
| CA2607940C (en) | 2005-05-18 | 2009-12-15 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| WO2007048224A1 (en) | 2005-10-25 | 2007-05-03 | Aegera Therapeutics Inc. | Iap bir domain binding compounds |
| CN101340947B (zh) * | 2005-12-20 | 2012-09-05 | 诺瓦提斯公司 | Iap-抑制剂和紫杉烷7的组合 |
| TWI543988B (zh) | 2006-03-16 | 2016-08-01 | 科學製藥股份有限公司 | 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物 |
| MY159563A (en) | 2006-05-16 | 2017-01-13 | Pharmascience Inc | Iap bir domain binding compounds |
| EP2049563B1 (en) | 2006-07-24 | 2014-03-12 | Tetralogic Pharmaceuticals Corporation | Dimeric iap antagonists |
| JP5452223B2 (ja) | 2006-07-24 | 2014-03-26 | テトラロジック ファーマシューティカルズ コーポレーション | Ｉａｐ阻害剤 |
| US20100056495A1 (en) * | 2006-07-24 | 2010-03-04 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| JP2010528587A (ja) * | 2007-05-07 | 2010-08-26 | テトラロジック ファーマシューティカルズ コーポレーション | アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてＴＮＦα遺伝子の発現を用いる方法 |
| ES2882855T3 (es) * | 2008-05-16 | 2021-12-02 | Dana Farber Cancer Inst Inc | Inmunomodulación por inhibidores de IAP |
| US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
| CN102612651A (zh) * | 2009-09-18 | 2012-07-25 | 诺瓦提斯公司 | Iap抑制剂化合物的生物标志物 |
| NZ602368A (en) | 2010-02-12 | 2014-10-31 | Pharmascience Inc | Iap bir domain binding compounds |
| UY33236A (es) * | 2010-02-25 | 2011-09-30 | Novartis Ag | Inhibidores dimericos de las iap |
| UY33794A (es) | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
| US9353419B2 (en) | 2012-05-04 | 2016-05-31 | Novartis Ag | Biomarkers for IAP inhibitor therapy |
| GB201305376D0 (en) * | 2013-03-25 | 2013-05-08 | Univ Leuven Kath | Novel viral replication inhibitors |
| CA2974651A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| KR102166292B1 (ko) * | 2018-11-13 | 2020-10-15 | 국민대학교 산학협력단 | 퀴논계 화합물을 유효성분으로 포함하는 피부 미백용 조성물 및 그 화합물의 스크리닝 방법 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2553871A1 (en) * | 2004-01-16 | 2005-08-04 | The Regents Of The University Of Michigan | Smac peptidomimetics and the uses thereof |
| WO2005097791A1 (en) * | 2004-04-07 | 2005-10-20 | Novartis Ag | Inhibitors of iap |
| PE20110224A1 (es) * | 2006-08-02 | 2011-04-05 | Novartis Ag | PROCEDIMIENTO PARA LA SINTESIS DE UN PEPTIDOMIMETICO DE Smac INHIBIDOR DE IAP, Y COMPUESTOS INTERMEDIARIOS PARA LA SINTESIS DEL MISMO |
-
2007
- 2007-10-17 KR KR1020097009957A patent/KR20090082221A/ko not_active Withdrawn
- 2007-10-17 RU RU2009118487/15A patent/RU2009118487A/ru not_active Application Discontinuation
- 2007-10-17 AU AU2007318220A patent/AU2007318220A1/en not_active Abandoned
- 2007-10-17 MX MX2009004061A patent/MX2009004061A/es not_active Application Discontinuation
- 2007-10-17 WO PCT/US2007/022125 patent/WO2008057172A2/en not_active Ceased
- 2007-10-17 US US12/446,430 patent/US20100316573A1/en not_active Abandoned
- 2007-10-17 JP JP2009533355A patent/JP2010507096A/ja active Pending
- 2007-10-17 CA CA002665838A patent/CA2665838A1/en not_active Abandoned
- 2007-10-17 BR BRPI0717411-0A2A patent/BRPI0717411A2/pt not_active IP Right Cessation
- 2007-10-17 EP EP07867238A patent/EP2076778A2/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010507096A5 (enExample) | ||
| JP3267635B2 (ja) | Ｃｏｘ−２阻害物質としてのインドール化合物 | |
| RU2461551C2 (ru) | Азолкарбоксамидное соединение или его фармацевтически приемлемая соль | |
| JP2013517283A5 (enExample) | ||
| MX2010004501A (es) | Inhibidor de la proteina de activacion de 5-lipoxigenasa (plap). | |
| JP3347136B2 (ja) | Ｃｏｘ−２阻害剤としての２，３−置換インドール化合物 | |
| JP2017160233A5 (enExample) | ||
| WO2008097538A8 (en) | Therapeutic agents | |
| WO2002051442A1 (en) | Concomitant drugs | |
| CY2014032I1 (el) | Νεα φαρμακα για τη θεραπεια της χρονιας αποφρακτικης πνευμονοπαθειας | |
| JP2004508357A5 (enExample) | ||
| MA28991B1 (fr) | Procede pour concentrer des anticorps, et produits therapeutiques correspondants | |
| JP2005517007A (ja) | ヒストンデアセチラーゼ阻害剤としての新規二環式ヒドロキサメート | |
| JP2012507535A5 (enExample) | ||
| JP2012530705A5 (enExample) | ||
| NZ598125A (en) | Apaf-1 inhibitor compounds | |
| NZ595553A (en) | VINYL INDAZOLYL COMPOUND; (E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol | |
| JP2009528354A5 (enExample) | ||
| JP2008518904A5 (enExample) | ||
| Rönn et al. | Evaluation of a diverse set of potential P1 carboxylic acid bioisosteres in hepatitis C virus NS3 protease inhibitors | |
| JP2018522581A5 (enExample) | ||
| EA200970875A1 (ru) | Производные индолизинуксусной кислоты в качестве антагонистов crth2 | |
| JP2008526988A5 (enExample) | ||
| JP2012520302A5 (enExample) | ||
| JP2003252854A (ja) | アンドロゲン受容体拮抗剤 |